May 17 (Reuters) - Valeant VRX.TO
* Statement regarding XiFaxan intellectual property litigation
* Says Salix Pharmaceuticals, Valeant and Actavis (NYSE:AGN) Laboratories Inc, at Actavis' request, have agreed to stay outstanding litigation
* Says companies have agreed to extend 30-month stay regarding Actavis' ANDA for a generic version of XiFaxan (Rifaximin) 550 mg tablets
* Says legal action is stayed through April 30, 2018 and cannot be lifted prior to Oct. 31, 2017
* Valeant says all currently scheduled litigation activities, including January 2018 trial date, have been indefinitely removed from court docket Source text for Eikon: ID:nPnbYHmK8a Further company coverage: VRX.TO